Freeline Therapeutics Holdings PLC (FRLN)
| Market Cap | 137.84M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -137.87M |
| Shares Out | 35.80M |
| EPS (ttm) | -5.06 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 59,985 |
| Open | 3.77 |
| Previous Close | 3.85 |
| Day's Range | 3.75 - 3.97 |
| 52-Week Range | 2.92 - 18.88 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 14.25 (+262.1%) |
| Est. Earnings Date | Nov 10, 2021 |
About FRLN
Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies for patients suffering from inherited systemic debilitating diseases. Its advanced product candidate is FLT180a, a gene therapy product candidate that is in Phase 1/2 dose-finding clinical trials in adult males for the treatment of hemophilia B. The company's products also include FLT190, which is in dose-escalating Phase 1/2 clinical trials for the treatment of Fabry disease; FLT201, a ...
Financial Performance
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for FRLN stock is "Buy." The 12-month stock price forecast is 14.25, which is an increase of 262.13% from the latest price.
News
Freeline Appoints Michael J. Parini as Chief Executive Officer and Reports Second Quarter 2021 Financial Results
On track for three programs in the clinic by year end; trial site initiation for FLT180a for Hemophilia B and FLT201 for Gaucher disease Type 1 expected by year end; program for FLT190 for Fabry disease...
Freeline Provides Executive Leadership Team Update; Company to Provide Corporate Update and Second Quarter 2021 Finan...
Guidance across all programs remains unchanged for expected data and clinical development milestones in 2021 Guidance across all programs remains unchanged for expected data and clinical development mil...
Freeline Announces Executive Leadership Changes
Appointment of Chief Technical Operations Officer James Bircher continues evolution of leadership team to execute across near- and long-term priorities
Freeline Doses Second Patient of Phase 1/2 MARVEL-1 Clinical Trial for Fabry Disease
Lowest dose cohort complete and study positioned for dose escalation
Freeline Reports First Quarter 2021 Financial Results and Recent Business Highlights
FLT190 Phase 1/2 dose-finding study in Fabry disease on track to dose additional patients; Company to present data by year-end
Freeline to Present Data at the American Society of Gene and Cell Therapy Annual Meeting 2021
LONDON, April 27, 2021 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage biotechnology company developing transformative gene therapie...
Freeline to Participate in Upcoming Investor Conferences in April and May 2021
LONDON, April 21, 2021 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage biotechnology company developing transformative AAV-mediated ...
Freeline Reports Full Year 2020 Financial Results and Business Highlights
Plans to have three AAV gene therapy programs in the clinic by year-end 2021
Freeline to Present at Upcoming Investor Conferences
LONDON, March 30, 2021 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage biotechnology company developing transformative gene therapie...
Freeline Presents Data on its Gaucher Disease and Fabry Disease AAV-Based Gene Therapies at the 17th Annual WORLDSymp...
Data demonstrate potential of FLT201 to deliver sustained levels of β-glucocerebrosidase (GCase) variant 85, a proprietary engineered GCase that penetrates target tissues in Gaucher disease
Freeline Therapeutics To Start FLT180a Dose Confirmation Study In Hemophilia B By 2021 End
Freeline Therapeutics Holdings Plc (NASDAQ: FRLN) has modified its FLT180a clinical development plan for Hemophilia B to address feedback received from the FDA regarding the characterization and compara...
Freeline to Present Data at the 2021 Virtual Congress of the European Association for Haemophilia and Allied Disorder...
LONDON, Jan. 26, 2021 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage, fully integrated, next generation, systemic AAV-based gene th...
Freeline to participate at Conferences during January 2021
LONDON, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage, fully integrated, next generation, systemic AAV-based gene th...
Freeline Reports Updated Data From Phase 1/2 B-AMAZE Trial in Hemophilia B
Updated dose-ranging data demonstrate potential for full normalization of FIX activity
Freeline to present at the 3rd Annual Evercore ISI Health CONx Conference
LONDON, Nov. 19, 2020 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage, fully integrated, next generation, systemic AAV-based gene th...
Freeline appoints Mark Baldry as Chief Commercial Officer
LONDON, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage, fully integrated, next generation, systemic AAV-based gene th...